A5057234589- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Uterine Myomas and Treatments
- Cervical Cancer and HPV Research
- Intraperitoneal and Appendiceal Malignancies
- Minimally Invasive Surgical Techniques
- Cancer-related molecular mechanisms research
- Endometriosis Research and Treatment
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- Chromatin Remodeling and Cancer
- Renal cell carcinoma treatment
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
- Genetics and Neurodevelopmental Disorders
- Immunotherapy and Immune Responses
- MicroRNA in disease regulation
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Circular RNAs in diseases
- Cancer Genomics and Diagnostics
- Gynecological conditions and treatments
- Genetic factors in colorectal cancer
Sungkyunkwan University
2016-2025
Samsung Medical Center
2016-2025
Genomics (United Kingdom)
2024
Kyungpook National University Hospital
2023-2024
KU Leuven
2024
Spanish Ovarian Cancer Research Group
2024
University Medical Center Hamburg-Eppendorf
2024
Centre Hospitalier Universitaire de Liège
2024
Universität Hamburg
2024
National Cancer Center
2024
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but as maintenance therapy is uncertain.
Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived (PDGFR) -α/-β, and c-Kit. Preclinical clinical studies support VEGFR PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role pazopanib maintenance therapy in patients with whose disease did not progress during first-line chemotherapy.Nine hundred forty histologically confirmed ovary, fallopian tube, or peritoneum, International Federation...
Abstract Purpose: MicroRNAs (miRNA) are small noncoding RNAs that 18 to 25 nucleotides in length; they regulate the stability or translational efficiency of target mRNAs. Emerging evidence suggests miRNAs might be involved pathogenesis a variety human cancers. Experimental Design: In this study, we profiled miRNA expression 10 early stage invasive squamous cell carcinomas (ISCC) and normal cervical epithelial specimens using TaqMan real-time quantitative PCR array methods. order evaluate...
Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated phase 3 investigation.
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients newly diagnosed advanced ovarian cancer and BRCA1 and/or BRCA2 (BRCA) mutation. We report overall (OS) after 7-year follow-up, clinically relevant time point longest follow-up for any first-line setting.This double-blind phase III trial randomly assigned BRCA mutation clinical response to...
Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.
Clear cell carcinoma (CCC) is a rare histologic subtype that demonstrates poor outcomes in epithelial ovarian cancer. The Japanese Gynecologic Oncology Group conducted the first randomized phase III, CCC-specific clinical trial compared irinotecan and cisplatin (CPT-P) with paclitaxel plus carboplatin (TC) patients CCC.Six hundred sixty-seven stage I to IV CCC of ovary were randomly assigned receive 60 mg/m(2) on days 1, 8, 15 day 1 (CPT-P group) every 4 weeks for six cycles or 175 area...
In SOLO1, maintenance olaparib (300 mg twice daily) significantly improved progression-free survival (PFS) for patients with newly diagnosed
Ovarian cancer is a leading cause of death in women. Early detection ovarian essential to decrease mortality. However, the early diagnosis difficult due lack clinical symptoms and suitable molecular diagnostic markers. Thus, identification meaningful tumor biomarkers with potential application clearly needed. To search for biomarker cancer, we identified human anterior gradient 2 (AGR2) from our systematic analysis paired normal tissue cDNA microarray. We noted marked overexpression AGR2...